Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
NCT05953038Phase 1Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of Lysergide, sponsored by Rigshospitalet. Primary endpoint: Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation at 24 hours. Started Nov 2023; status: active, not recruiting.
02
Drugs
Lysergide
Beyond the preview
Go deeper on NCT05953038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953038.